Quotient Sciences AAPS 2022 Poster, "Kilo Scale Synthesis in Daisy Chained Flow Reactors." (2R, 6R) hydroxynorketamine is a pharmaceutical undergoing trials as an antidepressant. An atom-efficient synthesis route with norketamine as an intermediate is known. A low throughput flow synthesis route to norketamine had previously been developed, 2 however a manufacturing scale method was required. The objective of this study is to conduct the entire synthesis of norketamine from 2 chlorophenylcyclopentyl ketone in daisy-chained reactors, built mainly from readily available parts at a throughput of > 1 kg/day.

Benznidazole pharmacokinetics in adults and children: Application of PBPK modelling to explore the impact of age on benznidazole pharmacokinetics, presented at the American Conference on Pharmacometrics (ACoP) 2022. Download a copy of Quotient Sciences scientific poster on "Benznidazole pharmacokinetics in adults and children: Application of PBPK modelling" here.

Download Quotient Sciences poster on the 'Development of a novel oral suspension formulation of a candidate API for administration to pediatric patients'.

Qualification of Gastroplus® PBPK modelling software to support decision-making in clinical development. Download Quotient Sciences resource today.

Download Quotient Sciences poster on 'A Phase I Study of the Cancer-specific Vaccine FMPV-1 in Healthy Male Subjects to Assess Safety and Immune Response'.

With a draft FDA guidance (Clinical Pharmacology Considerations for Human Radiolabelled mass Balance Studies, FDA, May 2022 ) under review there is currently considerable interest in the design and conduct of human mass balance studies. 

In the last 10 years Quotient Sciences have performed close to 200 radiolabelled studies. In that period, study designs have (where required) been adapted to address the challenges presented by new drug candidates, to benefit from new technologies and with a better understanding of how to interpret the data that can be generated from the analysis of collected samples. This poster reviews some of the outcomes from those programs. 

Presented as part of the 2022 The International Society for the Study of Xenobiotics (ISSX) conference in Seattle, WA, USA.

'Understanding the Absorption, Metabolism, and Excretion of Masitinib in Healthy Male Subjects'. Download our resource now to find out more.

Safety, tolerability, and pharmacokinetics of the oligomer modulator anle138b: a first-in-human randomized, double-blind, placebo-controlled Phase 1 trial.

The use of electrospraying as a means of drug loading into mesoporous silica particles for enhanced dissolution, presented at the 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical (PBP) Technology 2022.

Presented at CRS 2023, "Development of a Multi-Pill Abuse Resistant (MPAR®) Multiparticulate Modified Release Formulation to Prevent Opioid Overdose"